Jump to content

Spark Therapeutics: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Dimentow (talk | contribs)
159 edits
minor punctuation and grammar corrections
Roche acquisition completed
Line 3: Line 3:
| name = Spark Therapeutics
| name = Spark Therapeutics
| logo = Spark Therapeutics Label.png
| logo = Spark Therapeutics Label.png
| type = Public
| type = Subsidiary
| parent = [[Hoffmann-La Roche]]
| industry = [[Biotechnology]], [[Pharmaceutical]]
| industry = [[Biotechnology]], [[Pharmaceutical]]
| fate =
| fate =
| traded_as = {{NASDAQ|ONCE}}<br>[[Russell 2000 Index|Russell 2000 Component]]
| predecessor = <!-- or: | predecessors = -->
| predecessor = <!-- or: | predecessors = -->
| successor = <!-- or: | successors = -->
| successor = <!-- or: | successors = -->
Line 20: Line 20:
| num_employees =
| num_employees =
| num_employees_year = <!-- Year of num_employees data (if known) -->
| num_employees_year = <!-- Year of num_employees data (if known) -->
| parent =
| parent = [[Hoffmann-La Roche]]
| website = {{URL|sparktx.com}}
| website = {{URL|sparktx.com}}
}}
}}
Line 26: Line 26:
'''Spark Therapeutics''' is a startup pharmaceutical company that develops [[Gene therapy|gene therapies]].<ref>{{cite news |date=7 November 2017|title=Spark Therapeutics reports 3Q loss|url=https://uk.news.yahoo.com/spark-therapeutics-reports-3q-loss-124330729.html|work=[[Associated Press]]|access-date=16 November 2017}}</ref><ref name="PhilBiz1">{{cite news |first=John|last=George|date=7 November 2017|title=Spark, Pfizer amend agreement for experimental hemophilia gene therapy|url=https://www.bizjournals.com/philadelphia/news/2017/11/07/spark-pfizer-hemophilia-gene-therapy.html|work=[[Philadelphia Business Journal]]|access-date=16 November 2017}}</ref><ref>{{cite news |first=Marilynn|last=Marchione|date=10 October 2017|title=A gene therapy that could cure blindness is on the brink of getting approved|url=http://www.businessinsider.com/ap-seeing-hope-fda-panel-considers-gene-therapy-for-blindness-2017-10|work=[[Business Insider]]|access-date=16 November 2017}}</ref> It was founded in 2013 by [[Katherine A. High|Katherine High]] and Jeffrey Marrazzo in an effort to commercially develop treatments against haemophilia that High was working on at [[Children's Hospital of Philadelphia]].<ref>{{cite news |first=David|last=Crow|date=19 October 2017|title=Gene therapy helped these children see. Can it transform medicine?|url=https://www.ft.com/content/9c4fab50-b38f-11e7-a398-73d59db9e399|work=[[Financial Times]]|access-date=16 November 2017}}</ref>
'''Spark Therapeutics''' is a startup pharmaceutical company that develops [[Gene therapy|gene therapies]].<ref>{{cite news |date=7 November 2017|title=Spark Therapeutics reports 3Q loss|url=https://uk.news.yahoo.com/spark-therapeutics-reports-3q-loss-124330729.html|work=[[Associated Press]]|access-date=16 November 2017}}</ref><ref name="PhilBiz1">{{cite news |first=John|last=George|date=7 November 2017|title=Spark, Pfizer amend agreement for experimental hemophilia gene therapy|url=https://www.bizjournals.com/philadelphia/news/2017/11/07/spark-pfizer-hemophilia-gene-therapy.html|work=[[Philadelphia Business Journal]]|access-date=16 November 2017}}</ref><ref>{{cite news |first=Marilynn|last=Marchione|date=10 October 2017|title=A gene therapy that could cure blindness is on the brink of getting approved|url=http://www.businessinsider.com/ap-seeing-hope-fda-panel-considers-gene-therapy-for-blindness-2017-10|work=[[Business Insider]]|access-date=16 November 2017}}</ref> It was founded in 2013 by [[Katherine A. High|Katherine High]] and Jeffrey Marrazzo in an effort to commercially develop treatments against haemophilia that High was working on at [[Children's Hospital of Philadelphia]].<ref>{{cite news |first=David|last=Crow|date=19 October 2017|title=Gene therapy helped these children see. Can it transform medicine?|url=https://www.ft.com/content/9c4fab50-b38f-11e7-a398-73d59db9e399|work=[[Financial Times]]|access-date=16 November 2017}}</ref>


In February 2019, [[Roche Holding|Roche]] announced it would acquire the company for $4.3 billion ($114.50 per share).<ref>{{cite web|url=https://uk.reuters.com/article/us-spark-m-a-roche-hldg-idUKKCN1QE0L6|title=Roche 'steps up' for gene therapy with $4.3 billion Spark bet|date=25 February 2019|publisher=|via=uk.reuters.com}}</ref><ref>{{cite web |url=https://endpts.com/ftc-staff-sign-off-on-roche-4-3b-deal-for-spark-report/ |title=UPDATED: FTC staff signs off on Roche $4.3B deal for Spark — report |first=Natalie |last=Grover |date=25 October 2019 |website=EndpointNews }}</ref>
In February 2019, [[Roche Holding|Roche]] announced it would acquire the company for $4.3 billion ($114.50 per share).<ref>{{cite web|url=https://uk.reuters.com/article/us-spark-m-a-roche-hldg-idUKKCN1QE0L6|title=Roche 'steps up' for gene therapy with $4.3 billion Spark bet|date=25 February 2019|publisher=|via=uk.reuters.com}}</ref><ref>{{cite web |url=https://endpts.com/ftc-staff-sign-off-on-roche-4-3b-deal-for-spark-report/ |title=UPDATED: FTC staff signs off on Roche $4.3B deal for Spark — report |first=Natalie |last=Grover |date=25 October 2019 |website=EndpointNews }}</ref> In December 2019, the transaction was completed.<ref>{{cite web|url=https://www.bizjournals.com/philadelphia/news/2019/12/17/roche-completes-4-3b-purchase-of-philadelphia.html|title=Roche completes $4.3B purchase of Philadelphia gene therapy pioneer Spark Therapeutics|date=17 December 2019}}</ref>


==Products and pipeline==
==Products and pipeline==

Revision as of 15:12, 18 December 2019

Spark Therapeutics
Company typeSubsidiary
IndustryBiotechnology, Pharmaceutical
Founded2013; 11 years ago (2013) in Philadelphia, Pennsylvania, United States of America
FoundersJeffrey Marrazzo, Katherine High
Headquarters
Philadelphia
,
United States of America
ParentHoffmann-La Roche
Websitesparktx.com

Spark Therapeutics is a startup pharmaceutical company that develops gene therapies.[1][2][3] It was founded in 2013 by Katherine High and Jeffrey Marrazzo in an effort to commercially develop treatments against haemophilia that High was working on at Children's Hospital of Philadelphia.[4]

In February 2019, Roche announced it would acquire the company for $4.3 billion ($114.50 per share).[5][6] In December 2019, the transaction was completed.[7]

Products and pipeline

Voretigene neparvovec

Main article: Voretigene neparvovec

Voretigene neparvovec, marketed under the tradename Luxturna, is a gene therapy approved by the Food and Drug Administration for treatment of Leber's congenital amaurosis, a rare genetic eye disease.[8]

Fidanacogene elaparvovec

Fidanacogene elaparvovec, previously known by its study ID number SPK-9001,[9] is an experimental drug under investigation for treatment of hemophilia B. Spark partnered with pharmaceutical giant Pfizer to develop fidanacogene elaparvovec.[2] Fidanacogene elaparvovec is an adeno-associated viral vector which is designed to transfer a working copy of the Factor IX gene into the livers of patients who carry non-functioning copies.[10] In July 2018, Pfizer said fidanacogene elaparvovec was entering late stage clinical trials.[11]

SPK-8011

SPK-8011 is an experimental drug under investigation for treatment of hemophilia A. It is entering phase III clinical trials in the United States. The therapy transfers a working copy of the Factor VIII gene into patients who lack one. In Phase II clinical trials, 2 of 7 patients receiving the highest dose of the drug suffered immune responses. One patient had to be hospitalized. The reactions against the treatment were seen as a set back, though Spark suggested that the responses could be controlled with steroids, and promised to move forward with Phase III testing.[12][13]

SPK-7001

SPK-7001 is an experimental drug under investigation for treatment of choroideremia, a genetic disorder that causes blindness.[14]

SPK-3006

SPK-3006 is an experimental drug under investigation for treatment of Pompe disease, a genetic disorder that leads to failure to correctly metabolize glycogen.[14]

SPK-1001

SPK-1001 is an experimental drug under investigation for treatment of Batten disease, a fatal genetic, nervous system disorder.[14]

References

  1. ^ "Spark Therapeutics reports 3Q loss". Associated Press. 7 November 2017. Retrieved 16 November 2017.
  2. ^ a b George, John (7 November 2017). "Spark, Pfizer amend agreement for experimental hemophilia gene therapy". Philadelphia Business Journal. Retrieved 16 November 2017.
  3. ^ Marchione, Marilynn (10 October 2017). "A gene therapy that could cure blindness is on the brink of getting approved". Business Insider. Retrieved 16 November 2017.
  4. ^ Crow, David (19 October 2017). "Gene therapy helped these children see. Can it transform medicine?". Financial Times. Retrieved 16 November 2017.
  5. ^ "Roche 'steps up' for gene therapy with $4.3 billion Spark bet". 25 February 2019 – via uk.reuters.com.
  6. ^ Grover, Natalie (25 October 2019). "UPDATED: FTC staff signs off on Roche $4.3B deal for Spark — report". EndpointNews. {{cite web}}: no-break space character in |title= at position 61 (help)
  7. ^ "Roche completes $4.3B purchase of Philadelphia gene therapy pioneer Spark Therapeutics". 17 December 2019.
  8. ^ "FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss". FDA. 19 Dec 2017. Retrieved 20 Dec 2017.
  9. ^ "Pfizer Initiates Pivotal Phase 3 Program for Investigational Hemophilia B Gene Therapy" (Press release). Pfizer. 16 July 2018. Retrieved 2018-07-18.
  10. ^ Lindsey, George (1 December 2016). "Spk-9001: Adeno-Associated Virus Mediated Gene Transfer for Hemophilia B Achieves Sustained Mean Factor IX Activity Levels of >30% without Immunosuppression". Blood. 128 (22): 3. doi:10.1182/blood.V128.22.3.3. Retrieved 16 November 2017.
  11. ^ George, John (16 July 2018). "Pfizer begins late-stage testing of Spark's hemophilia B gene therapy". Philadelphia Business Journal. Retrieved 18 July 2018.
  12. ^ Garde, Damian (7 August 2018). "Spark's gene therapy data answer some burning questions — and raise a few more". Stat. Retrieved 7 August 2018.
  13. ^ Tirrell, Meg (7 August 2018). "Spark Therapeutics shares lose a third of their value as hemophilia gene therapy trial disappoints investors". CNBC. Retrieved 7 August 2018.
  14. ^ a b c Morrison, Chris (5 March 2019). "Spark's meteoric rise from hospital-funded spinout to $4.8 billion deal". Nature Biotechnology. Retrieved 8 February 2019.
Stub icon

This United States corporation or company article is a stub. You can help Wikipedia by expanding it.

Stub icon

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Spark_Therapeutics&oldid=931376285"